Adagio Therapeutics (Nasdaq: ADGI)

COVID-19 is not going away anytime soon, and after millions of deaths, billions of infections, unprecedented disease burden, and enormous economic costs, we continue to see major needs and opportunities. Progress with vaccines and therapeutics has been encouraging while variants of concern continue to plague progress, and the specter of new pandemics haunts our future. We invested in Adagio Therapeutics, led by world renowned experts in monoclonal antibody design, which is developing a portfolio of broadly neutralizing antibodies to address pandemic and endemic SARS-COV-2 and other viruses of pandemic potential.